Product Description
Fingolimod hydrochloride China manufacture 98%min 162359-56-0
AI Product Description
*The following content is generated by AI and is for reference only.
Fingolimod hydrochloride is a synthetic sphingosine analog developed primarily for the treatment of relapsing forms of multiple sclerosis (MS). As a prodrug, it is converted intracellularly to its active form, fingolimod-phosphate, which acts as a functional antagonist of sphingosine 1-phosphate (S1P) receptors. This mechanism traps lymphocytes within secondary lymphoid organs, preventing their migration into the central nervous system and thereby reducing inflammatory demyelination. The product is widely manufactured in China with high purity standards, typically meeting specifications of 98% minimum content, ensuring efficacy and safety for pharmaceutical applications.
The chemical identity of Fingolimod hydrochloride is defined by the molecular formula C20H35ClNO2P. Its corresponding CAS Registry Number is 167834-23-5. Structurally, it consists of a chiral cyclohexyl ring linked to an amino acid derivative, modified with a phosphate group and neutralized with hydrochloric acid to enhance solubility and stability. The Chinese manufacturing sector has established robust supply chains for this compound, adhering to Good Manufacturing Practices (GMP) to produce bulk active pharmaceutical ingredients (APIs) suitable for global distribution. These manufacturers focus on rigorous quality control to maintain the required 98% purity, minimizing impurities that could affect clinical outcomes.
Beyond its primary indication for MS, ongoing research explores potential therapeutic applications in other autoimmune disorders and transplant rejection management due to its immunomodulatory properties. The drug is administered orally, offering significant convenience over traditional injectable therapies. However, its use requires careful monitoring for initial cardiac effects, such as bradycardia, necessitating a first-dose observation period. The availability of high-quality Fingolimod hydrochloride from Chinese suppliers supports the global demand for effective MS treatments, facilitating cost-effective production of finished dosage forms. With its distinct mechanism of action and proven clinical efficacy, Fingolimod hydrochloride remains a cornerstone therapy in neurology, driving continuous innovation in pharmaceutical synthesis and regulatory compliance worldwide.